Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
Rhea-AI Summary
Abeona Therapeutics (Nasdaq: ABEO) reported full‑year 2025 results and operational updates on March 17, 2026. Key 2025 items include $5.8M total revenue, $191.4M cash and short‑term investments at year‑end, and a $152.4M net gain from the sale of a Rare Pediatric Disease PRV. ZEVASKYN commercial launch began in Q4 2025 with the first commercial patient treated in December; treatments and biopsies resumed after a manufacturing shutdown and continued in early 2026.
The company noted rising SG&A from commercialization, a $1.5M cost of sales tied to initial production and a transition of certain costs from R&D to inventory post FDA approval.
Positive
- PRV sale gross proceeds of $155.0M; net gain of $152.4M
- Cash, cash equivalents and short‑term investments of $191.4M
- Net income of $71.2M for 2025; EPS $1.34 basic
- First commercial ZEVASKYN patient treatment completed in December 2025
- Activation of UTMB in Galveston as fourth Qualified Treatment Center
Negative
- SG&A increased by $35.1M to $65.0M in 2025
- Cost of sales of $1.5M driven by initial treatment and unreleased batch
- August production batch not released due to assay technical challenges
- Net product revenue concentrated in a single December treatment
News Market Reaction – ABEO
In the Mar 17 session, ABEO declined 3.84%, reflecting a moderate negative market reaction. Argus tracked a trough of -6.2% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 12 | Q3 2025 earnings | Positive | +18.5% | Q3 update showed ZEVASKYN launch preparation, strong cash, and narrowing losses. |
| Aug 14 | Q2 2025 earnings | Positive | +10.2% | Reported FDA approval, launch plans, strong cash, and Q2 net income profitability. |
| May 15 | Q1 2025 earnings | Positive | +7.4% | Highlighted FDA approval, first center activation, PRV sale agreement, and solid cash. |
| Mar 20 | FY 2024 results | Neutral | -1.1% | Full-year 2024 loss but improved cash; outlined pz-cel regulatory and launch plans. |
| Nov 14 | Q3 2024 earnings | Positive | -2.5% | BLA resubmission accepted with PDUFA date and strong cash, yet shares fell modestly. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings and major financial updates have historically skewed positive for ABEO, with most such releases followed by upward price reactions, especially when tied to ZEVASKYN milestones and cash runway improvements.
Across the last five earnings-tagged releases from Nov 2024–Nov 2025, Abeona transitioned from pre-approval to commercial-stage for ZEVASKYN. The company moved from persistent net losses to periods of net income and repeatedly highlighted strong cash positions (e.g., $226M, $207.5M). ZEVASKYN milestones, payer coverage, and manufacturing scale-up have been central themes. Today’s full-year 2025 results continue that narrative, detailing first commercial treatments, revenue emergence, and profitability backed by the priority review voucher sale.
Key Terms
rare pediatric disease priority review voucher regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- First ZEVASKYN® commercial patient treatment completed in December -
- ZEVASKYN launch momentum building in first quarter 2026 –
-
CLEVELAND, March 17, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2025 and recent operational progress.
“2026 is about building a steady cadence of biopsies and treatments,” said Vish Seshadri, Chief Executive Officer of Abeona. “We are focused on ensuring every ZEVASKYN patient has a seamless experience throughout their treatment journey. Establishing these commercial foundations will position us to scale-up ZEVASKYN in 2026 and beyond.”
ZEVASKYN (prademagene zamikeracel) updates
- First ZEVASKYN commercial patient treatment completed in December; launch momentum building in first quarter 2026: Following the optimization of a release assay in 2025, ZEVASKYN commercial launch activities commenced in the fourth quarter, with the first patient treatment completed in December prior to a mandatory annual manufacturing facility shutdown. Since resuming manufacturing in late January 2026, multiple biopsies have been collected with additional biopsies expected this month. One patient has completed treatment with ZEVASKYN so far in 2026, and other collected biopsies are at various stages in the manufacturing process.
- Growing ZEVASKYN treatment experience expected to catalyze further ZEVASKYN demand: Growing ZEVASKYN treatment experience across the initial Qualified Treatment Center (QTC) network is establishing the institutional workflows and scalable foundation necessary to accelerate patient throughput and streamline the referral-to-treatment timeline. As the RDEB community shares in the positive experiences of the initial ZEVASKYN patients, the Company believes this will continue to catalyze sustained demand for ZEVASKYN.
- Abeona expands patient access to ZEVASKYN across Texas and the Gulf Coast region with activation of its newest QTC: In December, the Company announced activation of The University of Texas Medical Branch (UTMB), in Galveston, Texas, as the fourth QTC for ZEVASKYN. UTMB is a major academic medical center renowned for its expertise in comprehensive complex skin disease and wound care.
Full Year 2025 Financial Results
Abeona reported total revenue of
Net product revenue reflects the single patient treatment in December. While net product revenue reflects Medicaid coverage for the patient treated in December, the Company expects average net revenues to normalize over time as the payer mix expands to include commercially insured patients. Cash was received from the December treatment in the first quarter 2026.
Cost of sales for 2025 was
Total research and development (R&D) spending for 2025 decreased
Selling, general and administrative (SG&A) expenses for 2025 were
In May 2025, Abeona sold the Rare Pediatric Disease Priority Review Voucher (PRV) awarded following the FDA’s approval of ZEVASKYN. The Company received
Net income was
Cash, cash equivalents and short-term investments totaled
Conference Call Details
The Company will host a conference call and webcast on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its 2025 financial results and corporate progress. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 977217 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona’s website at https://investors.abeonatherapeutics.com/events. The archived webcast replay will be available for 30 days following the call.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN®, Abeona Assist™, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to successfully commercialize and market ZEVASKYN, including manufacturing sufficient batches of ZEVASKYN to meet demand; the therapeutic potential of ZEVASKYN; whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company’s expectations; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections by the FDA or other regulatory agencies, including those relating to preclinical programs and to the cGMP manufacturing of ZEVASKYN; the ability to achieve or obtain necessary regulatory approvals for our pre-clinical programs; our ability to execute on our key business priorities; the impact of any changes in the financial markets and global economic conditions, including those resulting from changes to U.S. or other countries’ trade policy, such as current or future tariffs; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise these forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
| ABEONA THERAPEUTICS INC. AND SUBSIDIARIES Consolidated Statements of Operations and Comprehensive Income (Loss) (In thousands, except share and per share amounts) | ||||||||
| For the years ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Revenues: | ||||||||
| Product revenue, net | $ | 2,420 | $ | — | ||||
| License and other revenues | 3,400 | — | ||||||
| Total revenues | 5,820 | — | ||||||
| Costs and expenses: | ||||||||
| Cost of sales | 1,532 | — | ||||||
| Royalties | 1,893 | — | ||||||
| Research and development | 26,812 | 34,360 | ||||||
| Selling, general and administrative | 65,031 | 29,851 | ||||||
| Total costs and expenses | 95,268 | 64,211 | ||||||
| Loss from operations | (89,448 | ) | (64,211 | ) | ||||
| Interest income | 5,556 | 4,246 | ||||||
| Interest expense | (3,740 | ) | (4,208 | ) | ||||
| Change in fair value of warrant and derivative liabilities | 6,139 | (755 | ) | |||||
| Gain from sale of priority review voucher, net | 152,366 | — | ||||||
| Other income, net | 410 | 1,194 | ||||||
| Income (loss) before income taxes | 71,283 | (63,734 | ) | |||||
| Income tax (benefit) expense | 100 | — | ||||||
| Net income (loss) | $ | 71,183 | $ | (63,734 | ) | |||
| Basic income (loss) per common share | $ | 1.34 | $ | (1.55 | ) | |||
| Dilutive income (loss) per common share | $ | 1.01 | $ | (1.55 | ) | |||
| Weighted average number of common shares outstanding: | ||||||||
| Basic | 52,952,917 | 41,048,206 | ||||||
| Dilutive | 66,135,821 | 41,048,206 | ||||||
| Other comprehensive income (loss): | ||||||||
| Change in unrealized gains related to available-for-sale debt securities | 130 | 74 | ||||||
| Comprehensive income (loss) | $ | 71,313 | $ | (63,660 | ) | |||
| ABEONA THERAPEUTICS INC. AND SUBSIDIARIES Consolidated Balance Sheets (In thousands, except share and per share amounts) | ||||||||
| December 31, 2025 | December 31, 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 78,437 | $ | 23,357 | ||||
| Short-term investments | 112,967 | 74,363 | ||||||
| Restricted cash | — | 338 | ||||||
| Accounts receivable, net | 6,147 | — | ||||||
| Inventory | 5,493 | — | ||||||
| Other receivables | 568 | 1,652 | ||||||
| Prepaid expenses and other current assets | 1,294 | 1,143 | ||||||
| Total current assets | 204,906 | 100,853 | ||||||
| Property and equipment, net | 9,921 | 4,430 | ||||||
| Operating lease right-of-use assets | 3,962 | 3,552 | ||||||
| Other assets | 781 | 96 | ||||||
| Total assets | $ | 219,570 | $ | 108,931 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 7,889 | $ | 3,441 | ||||
| Accrued expenses | 8,467 | 6,333 | ||||||
| Current portion of long-term debt | 12,222 | 5,926 | ||||||
| Current portion of operating lease liability | 864 | 823 | ||||||
| Accrued taxes | 126 | — | ||||||
| Other current liabilities | 2 | 64 | ||||||
| Total current liabilities | 29,570 | 16,587 | ||||||
| Long-term operating lease liabilities | 4,069 | 3,262 | ||||||
| Long-term debt | 7,813 | 13,037 | ||||||
| Warrant liabilities | 18,902 | 32,014 | ||||||
| Total liabilities | 60,354 | 64,900 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock - | — | — | ||||||
| Common stock - | 550 | 457 | ||||||
| Additional paid-in capital | 900,603 | 856,824 | ||||||
| Accumulated deficit | (742,075 | ) | (813,258 | ) | ||||
| Accumulated other comprehensive loss | 138 | 8 | ||||||
| Total stockholders’ equity | 159,216 | 44,031 | ||||||
| Total liabilities and stockholders’ equity | $ | 219,570 | $ | 108,931 | ||||
Contacts: Investor and Media Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.com Investor Lee M. Stern Meru Advisors lstern@meruadvisors.com